| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| ARK Investment Management · Cathie Wood | $468.1M | 3.04% | 4.55M | −28% | Q2 2026 |
| Bridgewater Associates · Ray Dalio | $1.9M | 0.01% | 18.65K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TWST trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 4, 2026 | Leproust Emily MChief Executive Officer | Sale at price 200.44 - 207.46 per share. | 4.5K | $919.37K |
| Oct 1, 2026 | Werner Robert F.Officer | Sale at price 188.88 per share. | 1.5K | $279.93K |
| Oct 1, 2026 | Laponis AdamChief Financial Officer | Sale at price 188.88 per share. | 8.1K | $1.52M |
| Oct 1, 2026 | Green PaulaOfficer | Sale at price 188.88 per share. | 10.1K | $1.91M |
| Oct 1, 2026 | Cho DennisOfficer | Sale at price 188.88 per share. | 9.5K | $1.80M |
| Oct 1, 2026 | Finn Patrick JohnPresident | Sale at price 188.88 per share. | 25.7K | $4.86M |
| Oct 1, 2026 | Leproust Emily MChief Executive Officer | Sale at price 188.88 - 200.00 per share. | 46.4K | $8.77M |
| Sep 20, 2026 | Green PaulaOfficer | Sale at price 165.49 per share. | 294 | $48.65K |
| Sep 20, 2026 | Cho DennisOfficer | Sale at price 165.49 per share. | 348 | $57.59K |
| Sep 20, 2026 | Leproust Emily MChief Executive Officer | Sale at price 165.49 per share. | 1.7K | $279.18K |
| Sep 16, 2026 | Leproust Emily MChief Executive Officer | Conversion of Exercise of derivative security at price 8.82 - 26.66 per share. | 208.7K | $4.22M |
| Sep 16, 2026 | Leproust Emily MChief Executive Officer | Sale at price 151.46 - 163.39 per share. | 356.5K | $56.33M |
| Sep 7, 2026 | Werner Robert F.Officer | Sale at price 122.62 per share. | 238 | $29.18K |
| Sep 7, 2026 | Green PaulaOfficer | Sale at price 122.62 per share. | 907 | $111.22K |
| Sep 7, 2026 | Cho DennisOfficer | Sale at price 122.62 per share. | 412 | $50.52K |
| Sep 7, 2026 | Leproust Emily MChief Executive Officer | Sale at price 122.62 per share. | 2.3K | $282.28K |
| Aug 24, 2026 | Leproust Emily MChief Executive Officer | Sale at price 150.56 - 154.45 per share. | 41.6K | $6.32M |
| Aug 23, 2026 | Werner Robert F.Officer | Sale at price 139.07 - 140.77 per share. | 1.5K | $213.25K |
| Aug 20, 2026 | Laponis AdamChief Financial Officer | Sale at price 139.07 per share. | 2K | $273.26K |
| Aug 20, 2026 | Green PaulaOfficer | Sale at price 139.07 per share. | 1.4K | $189.13K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 29.5 | 14.2 | 1.3 | 23.0 | 14.4 | 53.9 | -11.0 | 51.8 | 39.0 | -20.7 | +383.2% | ||
| 2025 | 12.7 | -25.9 | 1.1 | -2.4 | -23.5 | 25.6 | -8.8 | -19.7 | 4.3 | 16.9 | -2.7 | -0.9 | −31.7% |
| 2024 | -12.1 | 21.3 | -12.7 | -9.0 | 34.2 | 17.6 | 13.3 | -22.5 | 4.5 | -10.7 | 21.9 | -5.5 | +26.1% |
| 2023 | 20.5 | -32.2 | -22.5 | -17.2 | 21.4 | 35.0 | 19.0 | -9.7 | -7.9 | -22.2 | 52.6 | 53.3 | +54.8% |
| 2022 | -23.2 | -5.9 | -11.7 | -41.6 | 18.0 | 2.7 | 25.1 | -8.3 | -12.2 | -6.8 | -16.7 | -12.9 | −69.2% |
| 2021 | 16.5 | -16.3 | -10.0 | 8.3 | -20.0 | 24.2 | -7.7 | -8.0 | -5.5 | 11.1 | -19.6 | -19.0 | −45.2% |
| 2020 | 18.3 | 23.3 | -0.1 | 7.0 | 16.0 | 19.4 | 23.7 | 24.8 | 8.6 | 0.9 | 45.8 | 26.4 | +572.8% |
| 2019 | 0.2 | -5.9 | 6.5 | 2.1 | 9.1 | 12.4 | 16.2 | -13.9 | -17.7 | -0.3 | 0.0 | -11.9 | −9.1% |
| 2018 | 89.0 | -12.7 | +64.9% |
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc and Lilly TuneLab. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Buy / hold / sell counts